MolecuVax, Inc.

We are proud to announce the appointment of Dr. Thomas E. Ichim as Chief Executive Officer of MolecuVax, Inc. Dr. Ichim was appointed to the role of CEO on August 29, 2016. Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published 99 peer-reviewed articles and is co-editor of ...the textbooks RNA Interference: From Bench to Clinical Translation and Immuno-Oncology Text Book. Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr Ichim is inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development. Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

Proof-Of-Concept Clinical Trial with MVAX-001 MVAX-001 is a cellular immunotherapy developed by MolecuVax Inc, a San Diego Biotechnology Company, which is available at the Pan Am Cancer Treatment Center in Tijuana Mexico based on in-licensed patent from Therapeutic Solutions International, Inc. titled Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer A patent on means of manufacturing exosomes that possess high concentrations of proteins found ...on tumors, which are specifically optimized to stimulate the immune system of cancer patients as a new form of immunotherapy. Press Release on February 08, 2016. For more info: MVAX-001 MVAX-001 activates the immune system to seek and destroy cancer stem cells, based on their expression of a protein named Brother of the Regulator of Imprinted Sites (BORIS). MVAX-001 is generated using white blood cells of the patient, which are grown outside of the body to create dendritic cells. The patient’s own dendritic cells are treated in vitro with peptides derived from BORIS, and subsequently are injected back into the patient in order to program the immune response to kill cells that express the protein BORIS, which are cancer stem cells. Pan Am Cancer Treatment Center The Pan American Cancer Treatment Centers are a multispeciality group of Board Certified physicians and allied health professionals working together to meet the needs of patients and families living with chronic degenerative disease including cancer. We work to streamline the referral process, share information with other healthcare personnel, communicate and work with primary care physicians and case managers, research treatments and procedures to find the best options for treating the causes of degenerative disease, and participate in drug trials and research. The Pan Am Cancer Treatment Centers offer access to cutting edge cancer immunotherapies outside of clinical trials. Today safety of many immunotherapies has already been demonstrated, but the majority are currently in efficacy finding Phase III clinical trials. Unfortunately, in these trials, some patients are placed into the placebo group. The Pan Am Cancer Treatment Centers offer access to cellular, small molecule, and protein therapeutics through an accelerated means. In addition, novel combination immunotherapies are offered that are considered state of the art. Telephone: (619) 735-9581 Diego Rivera #2339 suite 108 Zona Rio, Tijuana B.C. 22010 www.cancerimmunotherapy.mx [email protected]

MolecuVax, Inc. Announces Licensing of Universal Cancer Vaccine With Demonstrated Efficacy in Breast Cancer May 09, 2016 09:00 ET Clinical Stage Immunotherapy Company Expands Its Intellectual Property Portfolio by Exclusive Licensing of Issued Patents ...Continue reading

MolecuVax, Inc. to Initiate Cancer Immunotherapy Clinical Trial Aimed at Eradicating Cancer Stem Cells Using MVAX-001 OCEANSIDE, CA(Marketwired April 11, 2016) Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an agreement between its subsidiary, MolecuVax, Inc., (MVAX) and the Pan Am Cancer Treatment Center covering production and clinical implementation of a novel cancer immunotherapy based around MVAX’s proprietary Brother of ...Continue reading

TSOI Announces the Licensing of Exosome Technology to MolecuVax, Inc. - February 08, 2016 09:00 ET OCEANSIDE, CA(Marketwired February 08, 2016) Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that the Company has licensed their Exosome Patent to MolecuVax, Inc. (MVAX) a wholly owned subsidiary of Therapeutic Solutions International, Inc. (TSI) where the intellectual property owned by TSI surrounding immune-oncology is housed. The programs...Continue reading